Question 1

What is Scorpion Capital?

Accepted Answer

Scorpion Capital is a Entity.

Question 2

How often does Scorpion Capital appear in global news?

Accepted Answer

Tracked across 3 news events drawn from 126 articles.

Question 3

When was Scorpion Capital first tracked by Ergen?

Accepted Answer

First tracked on Feb 15, 2025.

Question 4

When was Scorpion Capital last mentioned in news?

Accepted Answer

Last active on May 28, 2026.

Question 5

What is Scorpion Capital's current news sentiment?

Accepted Answer

Aggregate sentiment score: 53 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Scorpion Capital in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 3 events.

Question 7

What is the most recent event involving Scorpion Capital?

Accepted Answer

Soleno Therapeutics DCCR Securities Lawsuits (Apr 01, 2026, 83 articles).

Question 8

Who is Scorpion Capital most connected to?

Accepted Answer

Top relationships: TransMedics (activist), TransMedics (target), MiNK Therapeutics.

Question 9

How did the "Soleno Therapeutics DCCR Securities Lawsuits" event impact Scorpion Capital?

Accepted Answer

Scorpion Capital published a critical report on MiNK Therapeutics' drug candidate DCCR, alleging significant concerns regarding its safety, efficacy, and clinical trial data, which led to a decline in MiNK Therapeutics' stock price.

Question 10

How did the "Soleno Therapeutics Faces Class Action Lawsuits" event impact Scorpion Capital?

Accepted Answer

Scorpion Capital, an activist short seller, raised questions about MiNK Therapeutics' disclosures regarding DCCR, contributing to the stock price decline and subsequent lawsuits.

Question 11

How did the "Soleno Therapeutics Securities Fraud Lawsuit" event impact Scorpion Capital?

Accepted Answer

Scorpion Capital issued a report on August 15, 2025, which purportedly caused a disruption in DCCR's launch trajectory and revealed significant issues with MiNK Therapeutics' Phase 3 clinical trial program.

Question 12

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.